Editor’s Note
**Editor’s Note:** Dongkook Pharmaceutical is partnering with dermatologists to launch Madeca Labs, a dermacosmeceutical brand for clinical settings, set for release in the first half of 2027.
Dongkook Pharmaceutical is joining forces with dermatologists to develop ‘Madeca Labs’, a high-performance skincare brand tailored for hospital and clinic distribution channels. The target launch date is the first half of 2027.
According to Dongkook Pharmaceutical on the 26th, Madeca Labs is a dermacosmeceutical brand that combines the company’s R&D technology with the clinical experience and consultation of dermatologists.
The product line is expected to include items focused on improving the skin barrier, managing sensitive skin, post-procedure home care, and overall skin condition recovery.
To develop the brand, Dongkook Pharmaceutical established a dermacosmeceutical advisory board on June 13, comprising five dermatologists.
The advisory board includes Dr. Chun-sik Yoon (Yemiwon Dermatology Clinic), Dr. Ji-ho Park (Oaro Dermatology Clinic), Dr. Young-woon Park (Villad Skin Dermatology Clinic), Dr. Mi-hye Lee (Leewon Dermatology Clinic), and Dr. Sang-yeop Kim (JFCell Dermatology Clinic).
At the launch ceremony, Dongkook Pharmaceutical introduced its nearly 50 years of experience in plant-derived raw material research and its business plans in the dermacosmeceutical field. Discussions also covered the development direction and differentiation strategy for professional skincare products suitable for hospitals and clinics.
Attendees reviewed the mechanism of action on the skin and appropriate formulation design, focusing on the research results of ‘Centella Asiatica Standardized Extract (TECA)’, a key ingredient derived from Centella asiatica.
The advisory board plans to participate in overall product development through regular discussions, including selecting key ingredients, determining the full ingredient composition, formulation testing, and evaluating sensory attributes such as spreadability and absorption.
Following the launch of its dermacosmetic brand ‘Centellian24’ in 2015, Dongkook Pharmaceutical has been continuously expanding its hospital and clinic-exclusive brand ‘Madeca MD’ product line.
The company plans to simultaneously pursue the expansion of Madeca MD items and the development of Madeca Labs, strengthening its dermacosmeceutical business centered on professional hospital and clinic distribution networks.
